Startup Farsight Aiming for FDA Clearance of its Genomic Analysis Platform

Mar 27, 2018

Premium

CHICAGO (GenomeWeb) – Genomic analytics startup Farsight Genome Systems has high ambitions, seeking to gain US Food and Drug Administration clearance of its software for use in labs conducting sequencing-based tests.

"We would like to be the first analytic pipeline that has won FDA clearance," CEO and Founder Glenda Anderson said.

Sunnyvale, California-based Farsight, founded in 2015, has submitted a first demonstration of its Farsight Correo platform to the FDA, according to Anderson, as it seeks 510(k) clearance for the technology.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Mar

14

Featured Webinar

A Multiomics Approach to Defining the Nature of Early Malignant Transformations of the Immune System

In this webinar, Dr. Wendy Béguelin of Weill Cornell Medicine will discuss how she used the BD Rhapsody single-cell RNA-seq platform and YFP floxed reporter mouse models to study how lymphoma-associated mutations disrupt the immune system by affecting GC B-cell states, explaining the biology of initiation of low-grade follicular lymphoma.

Main menu